Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Farmers Insurance
Colorcon
Queensland Health
Argus Health
Chinese Patent Office
Covington
Federal Trade Commission
Dow
UBS

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 050775

« Back to Dashboard

NDA 050775 describes BIAXIN XL, which is a drug marketed by Abbvie and is included in one NDA. It is available from one supplier. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the BIAXIN XL profile page.

The generic ingredient in BIAXIN XL is clarithromycin. There are twenty-one drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the clarithromycin profile page.
Summary for 050775
Tradename:BIAXIN XL
Applicant:Abbvie
Ingredient:clarithromycin
Patents:2
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 050775
Suppliers and Packaging for NDA: 050775
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BIAXIN XL clarithromycin TABLET, EXTENDED RELEASE;ORAL 050775 NDA Physicians Total Care, Inc. 54868-4191 54868-4191-0 20 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (54868-4191-0)
BIAXIN XL clarithromycin TABLET, EXTENDED RELEASE;ORAL 050775 NDA Physicians Total Care, Inc. 54868-4191 54868-4191-1 1 BLISTER PACK in 1 BOTTLE, DISPENSING (54868-4191-1) > 14 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, EXTENDED RELEASE;ORALStrength500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Mar 3, 2000TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Apr 11, 2017Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF MILD TO MODERATE INFECTION CAUSED ABY SUSCEPTIBLE STRAINS
Patent:➤ SubscribePatent Expiration:Jun 15, 2017Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF MILD TO MODERATE INFECTION CAUSED ABY SUSCEPTIBLE STRAINS

Expired US Patents for NDA 050775

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie BIAXIN XL clarithromycin TABLET, EXTENDED RELEASE;ORAL 050775-001 Mar 3, 2000 ➤ Subscribe ➤ Subscribe
Abbvie BIAXIN XL clarithromycin TABLET, EXTENDED RELEASE;ORAL 050775-001 Mar 3, 2000 ➤ Subscribe ➤ Subscribe
Abbvie BIAXIN XL clarithromycin TABLET, EXTENDED RELEASE;ORAL 050775-001 Mar 3, 2000 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Cerilliant
Argus Health
Fuji
Farmers Insurance
Chinese Patent Office
Johnson and Johnson
Citi
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot